Brad Adams

Luminespib plus pemetrexed in patients with non-squamous non-small cell lung cancer.

D. Slamon, F. Braiteh, J. Goldman, 2019, Lung cancer.

Phase Ib/II single-arm trial evaluating the combination of everolimus, lapatinib and capecitabine for the treatment of HER2-positive with

D. Slamon, Rashi Singh, R. Callahan, 2018 .

Phase II randomized trial of a non-steroidal mouth wash for prevention and treatment of stomatitis in women with hormone receptor positive breast cancer treated with everolimus

D. Moore, S. Hurvitz, Xiaoyan Wang, 2020, Therapeutic advances in medical oncology.

Randomized phase II study of fulvestrant and erlotinib compared with erlotinib alone in patients with advanced or metastatic non-small cell lung cancer.

Patricia A. Young, R. Elashoff, J. Siegfried, 2018, Lung cancer.

Pathologic and molecular responses to neoadjuvant trastuzumab and/or lapatinib from a phase II randomized trial in HER2-positive breast cancer (TRIO-US B07)

Jennifer L. Caswell-Jin, A. Giuliano, C. Curtis, 2020, Nature Communications.

Phase Ib/II single-arm trial evaluating the combination of everolimus, lapatinib and capecitabine for the treatment of HER2-positive breast cancer with brain metastases (TRIO-US B-09)

D. Slamon, S. Hurvitz, Xiaoyan Wang, 2018, Therapeutic advances in medical oncology.

Abstract 4664: Result of TORI L-03, a randomized, multicenter phase II clinical trial of erlotinib (E) or E + fulvestrant (F) in previously treated advanced non-small cell lung cancer (NSCLC).

R. Elashoff, J. Siegfried, S. Dacic, 2013 .